Skip to content

Risk Reduction in Coronary Heart Disease

Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00679237
Acronym
SPREK!
Enrollment
1600
Registered
2008-05-16
Start date
2007-09-30
Completion date
2019-12-31
Last updated
2021-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Brief summary

Study hypothesis: Multifactorial risk reduction in coronary heart disease can reduce the risk of new coronary heart disease and death

Interventions

BEHAVIORALsmoking cessation

NRT and varenicline

DRUGbetablocker, diuretics, ACEI, ARB,

blood pressure control according to ESC guidelines

Cholesterol reduction according to ESC guidelines

BEHAVIORALtraining

daily walking

BIOLOGICALinfluenza vaccine

vaccine (FLuarix, Influvac etc)

DRUGmetformin, glimepiride, insulin

s.glucose control according to ESC guidelines

BEHAVIORALweight reduction

diet tips

Sponsors

Oslo University Hospital
CollaboratorOTHER
Sorlandet Hospital HF
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* acute myocardial infarction, CABG or PCI

Exclusion criteria

* Age \< 18 and age \> 80 * pregnant * critical illness * drug abuse

Design outcomes

Primary

MeasureTime frame
New cardiovascular events (MACE)3 years

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026